Merck Loses Bid For En Banc Rehearing In Fosamax Patent Case
The U.S. Court of Appeals for the Federal Circuit has denied Merck's petition for an en-banc rehearing of a panel's decision that invalidated one of the patents for its best-selling osteoporosis...To view the full article, register now.
Already a subscriber? Click here to view full article